Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how IQVIA turns billions of clinical data points into revenue can feel like decoding a medical registry. Key figures on contract research backlogs, technology licensing, and goodwill impairment are scattered across dense reports, and keeping up with IQVIA insider trading Form 4 transactions adds another layer of complexity. Investors who type “IQVIA SEC filings explained simply” need more than raw documents—they need answers. Stock Titan’s AI reads every line the moment it hits EDGAR and highlights what matters.
Whether you’re hunting for the latest IQVIA quarterly earnings report 10-Q filing, comparing cash-flow trends inside an IQVIA annual report 10-K simplified, or needing IQVIA Form 4 insider transactions real-time, our platform delivers. We pair line-by-line machine learning with human-trained models, turning raw data into plain-English takeaways. Drill into revenue by segment, R&D capitalization, or debt covenants in seconds—understanding IQVIA SEC documents with AI becomes straightforward. Each page also links to thorough IQVIA earnings report filing analysis prepared by our research desk, so you can move from numbers to narrative without opening a spreadsheet.
Looking beyond quarterly results, Stock Titan monitors every event that could move the share price. Receive instant alerts when IQVIA 8-K material events explained—think acquisitions, data breaches, or leadership changes—are posted. Explore IQVIA executive stock transactions Form 4 to gauge management sentiment, and review the IQVIA proxy statement executive compensation section to see how performance metrics align with pay. With real-time updates, AI-powered summaries, and historical search across all forms, you’ll spend less time digging and more time deciding.
IQVIA Holdings insider activity: A senior executive reported several stock transactions in IQVIA Holdings Inc. common stock on 12/18/2025. The filing shows an exercise of 50,000 stock appreciation rights at an exercise price of $59.90 per share, resulting in the acquisition of 50,000 shares of common stock.
On the same date, the executive sold 36,564 shares of common stock in open-market transactions at a weighted average price of $222.43 per share, and a further 13,436 shares at $222.91 per share. Following these transactions, the executive directly owned 807,163 shares of IQVIA common stock and indirectly owned 543,302 shares through the Orohena Trust.
A planned Rule 144 sale has been filed for IQV common stock. The notice covers 36564 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of 8132875.67, while 170300000 shares are outstanding. The approximate sale date listed is 12/18/2025 on the NYSE.
The filing also discloses that Ari Bousbib sold 56557 common shares of the same issuer on 10/29/2025, generating gross proceeds of 12460983.24. These details show both the upcoming planned transaction and recent sales over the prior three months, as required under Rule 144 disclosure rules.
IQVIA Holdings Inc. reported that it entered into an amendment to its Fifth Amended and Restated Credit Agreement. The amendment refinances existing Term A-1 and Term A-2 dollar term loans into a new class of term A dollar loans, and refinances existing term A euro loans into a new class of term A euro loans. It also consolidates all current U.S., Japanese, and Swiss/Multicurrency revolving credit commitments into a new class of revolving credit commitments.
The amendment reduces the interest rate on term A loans and revolving credit loans denominated in U.S. dollars by eliminating the term SOFR credit spread adjustment. In addition, the Swiss Subsidiary Borrower and the Japanese Borrower are released from all obligations as borrowers under the credit agreement.
IQVIA Holdings Inc. (IQV): A newly appointed director, William G. Kaelin, Jr., filed a Form 3 initial statement of beneficial ownership. The filing indicates no securities are beneficially owned as of the event date 11/05/2025. The relationship is listed as Director, and the form was filed by one reporting person. The submission was signed by an attorney-in-fact.
IQVIA (IQV) director Leslie Wims Morris reported acquiring 146 deferred share units on 11/05/2025, coded as an award (A), at a disclosed derivative price of $210.12. Following the transaction, she beneficially owns 4,735 deferred share units, held directly.
Each deferred share converts into one share of common stock upon settlement. Per the plan, settlement occurs when the director service ends, upon a change in control, or upon death; there is no expiration date.
IQVIA Holdings (IQV): Form 4 shows director equity activity. Director Colleen A. Goggins acquired 181 deferred share units on 11/05/2025 at $210.12 each. Following the transaction, she holds 4,702 deferred share units directly.
Each deferred share converts 1-for-1 into IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, settlement occurs when the director ceases service, upon a change in control, or upon death. The deferred shares have no expiration date.
IQVIA Holdings Inc. (IQV) reported an insider equity change as a director acquired 193 deferred shares on 11/05/2025 at a recorded derivative security price of $210.12, according to a Form 4 filing.
Each deferred share is convertible into one share of common stock upon settlement, which occurs when the director ceases to serve, upon a change in control of the company, or upon death, with no expiry date. Following this transaction, the director beneficially owned 4,063 deferred share units directly.
IQVIA Holdings (IQV): Director Form 4 update. Director John G. Danhakl reported acquiring 158 deferred shares on 11/05/2025 at a price of $210.12 per unit. Following this transaction, he beneficially owned 2,772 derivative securities.
These deferred shares convert into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, settlement occurs when the director leaves the board, upon a change in control of the company, or upon the director’s death. The deferred shares have no expiration date. Ownership is reported as direct.
IQVIA Holdings Inc. appointed William G. Kaelin Jr., M.D. to its Board of Directors on November 5, 2025. The Board determined that Dr. Kaelin meets the New York Stock Exchange definition of an independent director. In connection with the appointment, he is expected to enter into the company’s standard indemnification agreement for non-management directors and will participate in the non-employee director compensation program described under “Director Compensation” in the proxy statement dated February 28, 2025. The company announced the appointment via a press release attached as Exhibit 99.1.
IQVIA Holdings Inc. (IQV): Executive Vice President and General Counsel Eric Sherbet reported insider transactions on 10/29/2025. He exercised stock appreciation rights at $131.82 to acquire 10,000 shares, then sold 4,000 shares at a weighted average price of $219.70 (ranging from $219.66 to $219.92) and 6,000 shares at $219.72. Following these trades, he directly owns 21,108 shares. The SARs related to 10,000 underlying shares (exercisable since 02/13/2022, expiring 02/13/2029), with 8,436 derivative securities remaining beneficially owned.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
